OLVIG
TSHA icon

Oliver Lagore Vanvalin Investment Group’s Taysha Gene Therapies TSHA Stock Holding History

Oliver Lagore Vanvalin Investment Group’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,800
Closed -$5.63K – 732
2024
Q3 		$5.63K Buy
+2,800
New +$6.14K ﹤0.01% 490

Other funds holding TSHA

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Oliver Lagore Vanvalin Investment Group's TSHA Position: Q4 2024 in Review

Oliver Lagore Vanvalin Investment Group sold out of Taysha Gene Therapies (TSHA) in Q4 2024, closing a stake of 2,800 shares — an estimated $5.63K sold.

Oliver Lagore Vanvalin Investment Group first reported a position in TSHA in Q3 2024 and held it in 1 quarter. The position peaked at $5.63K in Q3 2024. 131 funds tracked by Wall St. Rank hold TSHA as of Q4 2024.

  • Oliver Lagore Vanvalin Investment Group reported no remaining Taysha Gene Therapies position as of Q4 2024 after selling out during the quarter.
  • Oliver Lagore Vanvalin Investment Group sold 2,800 Taysha Gene Therapies shares in Q4 2024, an estimated $5.63K.
  • Oliver Lagore Vanvalin Investment Group first reported a position in Taysha Gene Therapies in Q3 2024 and held it in 1 quarter.
  • Oliver Lagore Vanvalin Investment Group's Taysha Gene Therapies position peaked at $5.63K in Q3 2024.
  • 131 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q4 2024.

Based on Oliver Lagore Vanvalin Investment Group's 13F filing for Q4 2024, filed 1 Apr 2025.